Bombay HC restrains firm from infringing Sun Pharma trademark Prolomet
The Bombay High Court has noted an ad-interim injunction restraining the Salud Care (India) Private from using trademark PROLOMEK or any other trademark that is identical with or deceptively or confusingly similar to Sun Pharma Laboratories Ltd's mark PROLOMET.
The order was issued during a hearing conducted by G S Patel through video conferencing, deliberating the case filed by Sun Pharma. The counsel for Sun Pharma informed the court that in April 2021, Sun Pharma learned that Salud Care (India) Private markets a pharmaceutical preparation for the treatment of hypertension with tachycardia, angina, hyperthyroidism, and myocardial infarction with the same based drug, Metoprolol Succinate, under the trade mark PROLOMEK.
For more details, check out the full story on the link below:
Bombay HC Restrains Firm From Infringing Sun Pharma Trademark Prolomet
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.